Analysts Set Expectations for CATX FY2024 Earnings

Perspective Therapeutics, Inc. (NYSE:CATX) – Equities researchers at Cantor Fitzgerald issued their FY2024 earnings per share (EPS) estimates for Perspective Therapeutics in a note issued to investors on Tuesday, March 4th. Cantor Fitzgerald analyst L. Watsek forecasts that the company will earn ($0.90) per share for the year. Cantor Fitzgerald has a “Strong-Buy” rating on the stock. The consensus estimate for Perspective Therapeutics’ current full-year earnings is ($0.88) per share. Cantor Fitzgerald also issued estimates for Perspective Therapeutics’ FY2025 earnings at ($1.09) EPS.

CATX has been the topic of a number of other reports. Royal Bank of Canada restated an “outperform” rating and set a $16.00 price target on shares of Perspective Therapeutics in a research note on Tuesday, January 14th. Bank of America cut Perspective Therapeutics from a “buy” rating to a “neutral” rating and decreased their price target for the stock from $24.00 to $5.00 in a research note on Monday, November 25th. Oppenheimer decreased their price target on Perspective Therapeutics from $22.00 to $16.00 and set an “outperform” rating on the stock in a research note on Friday, November 22nd. Finally, Wedbush restated an “outperform” rating and set a $11.00 price target on shares of Perspective Therapeutics in a research note on Friday, January 24th. One analyst has rated the stock with a hold rating, seven have given a buy rating and one has issued a strong buy rating to the company’s stock. Based on data from MarketBeat.com, the company currently has an average rating of “Buy” and an average price target of $15.14.

Perspective Therapeutics Trading Up 6.7 %

CATX opened at $2.70 on Thursday. Perspective Therapeutics has a one year low of $2.32 and a one year high of $19.05. The business’s 50 day moving average price is $3.22 and its 200 day moving average price is $7.84.

Institutional Trading of Perspective Therapeutics

Several hedge funds have recently modified their holdings of the stock. The Manufacturers Life Insurance Company raised its stake in shares of Perspective Therapeutics by 8.9% in the third quarter. The Manufacturers Life Insurance Company now owns 20,514 shares of the company’s stock valued at $274,000 after acquiring an additional 1,672 shares in the last quarter. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC raised its stake in shares of Perspective Therapeutics by 5.8% in the third quarter. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC now owns 58,678 shares of the company’s stock valued at $783,000 after acquiring an additional 3,211 shares in the last quarter. BNP Paribas Financial Markets raised its stake in shares of Perspective Therapeutics by 7.4% in the fourth quarter. BNP Paribas Financial Markets now owns 51,094 shares of the company’s stock valued at $163,000 after acquiring an additional 3,529 shares in the last quarter. US Bancorp DE raised its stake in shares of Perspective Therapeutics by 142.7% in the third quarter. US Bancorp DE now owns 6,576 shares of the company’s stock valued at $88,000 after acquiring an additional 3,866 shares in the last quarter. Finally, Rhumbline Advisers raised its stake in shares of Perspective Therapeutics by 4.5% in the fourth quarter. Rhumbline Advisers now owns 94,992 shares of the company’s stock valued at $303,000 after acquiring an additional 4,075 shares in the last quarter. 54.66% of the stock is currently owned by institutional investors and hedge funds.

Perspective Therapeutics Company Profile

Perspective Therapeutics, Inc, together with its subsidiaries, develops precision-targeted alpha therapies (TAT) for oncology that treats cancer patients across multiple tumor types comprising metastatic disease. The company discovers, designs, and develop its initial programs candidates consists of VMT-a-NET, that is currently in Phase 1/2a clinical trials for patients with unresectable or metastatic somatostatin receptor type 2 (SSTR2) expressing tumors that have not previously received peptide-targeted radiopharmaceutical therapy, such as Lutathera, a beta-emitting therapy; and VMT01, which is currently in Phase 1/2a clinical trials for second-line or later treatment of patients with progressive melanocortin 1 receptor (MC1R) positive metastatic melanoma.